Our Team
Our team includes world-leading experts in molecular biology, medicinal chemistry and artificial intelligence from several research institutions including Harvard University, Stanford University, National University of Singapore, Karolinska Institute, and University College London. Our team members bring extensive industry experience from companies such as Johnson & Johnson, BeiGene, and AstraZeneca, ensuring a seamless integration of scientific excellence with industry innovation.
Ling Wu, PhD
-
Dr. Wu Ling is a seasoned cancer immunologist with over a decade of experience in therapeutics. He was formerly a group leader at BeiGene and serves as an advisor to the International Society of Pharmaceutical Engineering (ISPE). He holds a PhD from the National University of Singapore and is a recipient of the Outstanding Research Award.
Jie Sun
-
Sun Jie is an AI specialist with deep experience in health data science and AI-driven drug development. She held data science roles at Dana-Farber and Mass General, with research published in The Lancet and AAAI. Previously, she cofounded Basys.ai, a healthtech startup backed by the Mayo Clinic and Eli Lilly. A 40 Under 40 honoree by the Boston Congress of Public Health, she mentors startups at MIT, NUS, and MassChallenge, and writes on AI and entrepreneurship for Forbes. She holds an MS in Health Data Science from Harvard and a BS in Statistics from NUS.
Charles Cooney
-
Prof. Charles Cooney is an Advisor to ChemT Biotechnology and a Professor Emeritus of Chemical Engineering at MIT. A pioneer in bioprocessing and pharmaceutical manufacturing, he has authored more than 250 publications and holds over 25 patents. Prof. Cooney has served on the boards of more than 25 biotechnology and pharmaceutical companies, including Codiak Bioscience, Innovent Biologics, and Levitronix Technologies. His expertise spans scalable biologics production, regulatory strategy, and biomanufacturing innovation.
Prof. Nicholas Gascoigne
-
Prof. Nicholas is a world-renowned immunologist and Fellow of the Royal Society of Biology. A pioneer in T cell biology, he co-discovered the TCR gene with Mark Davis and has over 30 years of research experience. Former President of the Singapore Immunology Society, his work has been cited over 10,000 times, including publications in Nature and Science.
https://medicine.nus.edu.sg/mbio/about-us/our-people/academic-staff/nicholas-gascoigne.html
Kheng Nam
-
Kheng Nam Lee, Senior Advisor to ChemT, is Deputy Chairman of Vertex Venture Holdings and a Venture Partner at Granite Asia. With decades of deep-tech and venture leadership across government and industry, he serves on multiple technology boards and has guided several companies through successful acquisitions.
Hancheng Zhang, PhD
-
Dr Zhang is a seasoned medicinal chemist with 15+ years at Johnson & Johnson leading small-molecule drug design, followed by roles as SVP of Chemistry at ChemPartner (managing 300+ scientists) and founder of Innogate Pharma. He is also the former president of the Sino-America Pharmaceutical Professionals Association.
News and Insights
Innovate, Enhance, Cure
-
ChemT Biotechnology and CARsgen Therapeutics Announce Strategic Partnership to Advance Cell Therapy Innovation
Singapore, Dec 2025 — ChemT Biotechnology and CARsgen Therapeutics have entered into a strategic partnership focused on accelerating next-generation cell therapy development and exploring potential IND-enabling collaboration opportunities.
-
ChemT Marks a Milestone Moment on the NASDAQ Times Square Tower
New York, Nov 2025 – ChemT Biotechnology was featured on the NASDAQ Times Square tower in New York, marking the conclusion of its participation in the BioTools Innovator 2025 cohort. The milestone reflects a year of rapid progress in advancing its AI-powered biotechnology platform.
-
ChemT Becomes the First Singapore Company to Win the Lee Kuan Yew Global Business Plan Competition
Singapore Nov 2025- ChemT Biotechnology has made history as the first Singapore company to win the Grand Prize at the 12th Lee Kuan Yew Global Business Plan Competition (LKYGBPC), organised by the Institute of Innovation and Entrepreneurship at Singapore Management University (SMU).
-
ChemT Biotechnology Co-Founders to Speak at ISPE Singapore Conference 2025
Singapore, August 2025 – ChemT Biotechnology Co-Founders Dr. Ling Wu and Ms. Jie Sun will speak at the ISPE (International Society for Pharmaceutical Engineering) Singapore Conference 2025, held 27–29 August at Suntec Singapore.
-
ChemT Biotechnology Joins Ignition AI Accelerator
Singapore, August 2025 – ChemT Biotechnology has been selected for the Ignition AI Accelerator Program, an initiative backed by Tribe, NVIDIA, and Digital Industry Singapore (DISG) to advance high-impact AI innovations.
-
ChemT Biotechnology Unveils New Packaging for Flagship Product
Singapore, July 2025 – ChemT Biotechnology has introduced new packaging for its first commercial product, marking a milestone in the company’s journey from R&D to market delivery. The updated design reflects ChemT’s commitment to quality, innovation, and customer experience.
-
ChemT Biotechnology Becomes First Singapore Company Selected for BioTools Innovator 2025 Accelerator
Singapore, June 2025 – ChemT Biotechnology has been selected for the BioTools Innovator 2025 Accelerator Program, one of the world’s leading accelerators for the biotech sector. This year’s program saw over 420 applicants from around the globe, with only 30 companies chosen — making ChemT the first Singapore-based company in the program’s history.
-
ChemT Biotechnology Showcases Chemplify at ISCT 2025 in New Orleans
New Orleans, May 2025 – ChemT Biotechnology President and Cofounder Dr. Ling Wu participated in the International Society for Cell & Gene Therapy (ISCT) 2025 conference in New Orleans, engaging with global leaders in cell therapy and highlighting its proprietary AI-designed small molecule, Chemplify, that directly addresses T-cell senescence, a universal bottleneck in cell therapy manufacturing.
-
ChemT Biotechnology Presents AI Strategy to Address Biologics Bottlenecks at BILS 2025
Singapore, April 15, 2025 – ChemT Biotechnology took part in the Bio Innovation Leaders Summit (BILS) held in Singapore this week. Co-founder Dr. Ling Wu delivered a keynote address on leveraging artificial intelligence to enhance efficiency in biologics manufacturing.
-
ChemT Co-Founders Discuss AI’s Role in Drug Discovery at April 2025 Panel
Singapore April 2025 – ChemT Biotechnology Co-Founders Ms. Jie Sun and Dr. Ling Wu joined industry leaders John Ng of Dark Horse Consulting, Sen (Sean) Lin of ChemLex, and Dr. Qiusong Tang of Roche in an April 2025 panel on the future of artificial intelligence in drug discovery and biologics manufacturing.
-
ChemT Biotechnology Received a Letter of Support from Cytiva to Advance Cell Therapy Manufacturing
Singapore, December 20, 2024 – ChemT Biotechnology is working closely with Cytiva, a global leader in bioprocessing and cell therapy technologies, to support innovation and progress in cell therapy manufacturing. The collaboration focuses on integrating ChemT Bio’s flagship product, Chemplify™, into key stages of T cell production.
-
ChemT Biotechnology Appoints Biomanufacturing Pioneer Prof. Charlie Cooney as Advisor
Singapore, December 15, 2024 – ChemT Biotechnology is delighted to welcome Prof. Charlie Cooney, Robert T. Haslam Professor Emeritus of Chemical Engineering at MIT, as an advisor to the company.
-
ChemT Biotechnology Recognized by NUS Alumni Magazine for Advancing AI in Biologics Manufacturing
Singapore, June 15, 2024 – ChemT Biotechnology was recently featured in the NUS Alumni Magazine for its pioneering work in applying artificial intelligence to biologics manufacturing.
